127 results about "Colneleic acid" patented technology

The invention discloses a nonionic organosilicon surfactant. By means of the surfactant, the distance between siloxane and a hydrophilic group is lengthened, and the hydrolysis resistance of siloxane can be effectively improved. The nonionic organosilicon surfactant has the structure of a structural formula I as follows: in the structural formula I, m ranges from 1 to 100, and n ranges from 0 to 20; R represents mono-functionality polyether ester with a structure as follows: in the structure of mono-functionality polyether ester, R1 represents CH3CH2, CH3CH2CH2, CH(CH3)2 or CH3CH2CH2CH2; R2 represents an alkyl part of alpha-gadoleic acid or unsaturated fatty acid; and x ranges from 20 to 120, and y ranges from 0 to 75.

An orally or parenterally administered composition for reducing the storage of lipids in a human, the composition comprising: an effective amount of hydroxycitric acid; an effective amount of carnitine; an effective amount of biotin; an effective amount of one or more gluconeogenic substrates selected from the group consisting of: aspartate, lactate, glycerol, and a gluconeogenic amino acid or alphaketo analogue thereof; an effective amount of eicosapentanoic acid; and an effective amount of one or more ingredients selected from the group consisting of: medium chain triglycerides (MCT) with fatty acid backbones containing 6 to 14 carbon atoms or their individual fatty acid analogues or metabolic precursors, sesame seeds or derivative products, sesamin and/or its epimer episesamin, caffeine, forskolin, 7-keto dehydroepiandrosterone (7-keto DHEA), green tea extract containing epigallocatechingallate (EGCG), capsaicum, and 5-hydroxytryptophan (5-HTP). The supplement may also be combined with a food, beverage, condiment, spice or salad dressing base to provide a food, beverage, condiment, spice or salad dressing product designed to reduce lipid storage.

A method for extracting a phospholipid rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is characterized in that firstly marine animal materials are grinded into homogenate solution with colloid; the homogenate solution is frozen and dried and then crushed through a crushing mill; neutral fat and cholesterol in the material powder are removed through supercritical carbon dioxide; and then the phospholipid is extracted with ethanol aqueous solution. The product extracted through the method has high yield and purity; the extraction process has no pollution to the environment and the production staff; the extracted product can promote growth and development of infant brain, enhance memory, promote infant optic nerve and retina development and prevent and cure heart vascular diseases, and has anti-inflammatory, anti-cancer, immunity-enhancing and other physical activities, thereby having higher development and utilization value as health care products or raw materials of medicine.

An omega-3 oil concentrate comprising at least 70 weight percent of eicosapentaenoic acid [“EPA”; cis-5,8,11,14,17-eicosapentaenoic acid; omega-3], measured as a weight percent of oil, and substantially free of docosahexaenoic acid, said concentrate obtained from a microbial oil having 30 to 70 weight percent of eicosapentaenoic acid, measured as a weight percent of total fatty acids, and substantially free of docosahexaenoic acid and wherein said microbial oil is obtained from a microorganism that accumulates in excess of 25% of its dry cell weight as oil. Also disclosed are methods of making such eicosapentaenoic acid concentrates.

Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of Δ⁵ desaturase, and optionally stearidonic acid or ω-3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.

The invention relates to an unsaturated fatty acid feed addictive capable of improving quality of skin and hair of cats and dogs, wherein the feed addictive comprises unsaturated fatty acids or their ester derivatives whose weight ratio is, linoleic acid 82.2-88.3, arachidonic acid 0.8-2.7, linolenic acid 8.5-14.8, EPA and DHA 0.5-2.2. The additive can reinforce the growth of fur-bearing animals especially the growth of nervous systems of cats and dogs.

The invention relates to a process for producing nylon 11 resin by utilizing castor oil, in particular to a method for preparing 11-aminoundecanoic acid by utilizing 10-undecenoic acid. The method comprises the following steps: proportioning 10-undecenoic acid, methylbenzene and benzene to prepare a raw material solution, and generating 11-bromoundecanoic acid by virtue of the additive reaction of the raw material solution with hydrogen bromide in a double-kettle reaction device in the presence of catalyst; ammonolyzing the 11-bromoundecanoic acid by virtue of three different processing ways without the crystallization; adding a phase-transfer catalyst in the ammonolysis reaction to accelerate the ammonolysis reaction; carrying out vacuum filtering after the ammonolysis reaction is completed, wherein a filter cake is a 11-aminoundecanoic acid crude product; adding the crude product into the deionized water, dissolving the crude product by heating the crude product, cooling and crystallizing the crude product, and filtering the crude product to obtain the refined 11-aminoundecanoic acid product.

The invention provides a preparation method and device for polyenoic acid and an ester monomer thereof. The polyenoic acid and the ester monomer thereof are prepared by combining a primary short-range distillation method without consumption of an organic solvent with a supercritical carbon dioxide fluid chromatography. The short-range distillation technology is used for pre-separating long-chain compounds, polar compounds and volatile compounds in the raw materials of the polyenoic acid and the ester thereof to relieve the pressure of supercritical carbon dioxide fluid chromatographic separation and avoid polluting a chromatographic column, so that the polyenoic acid and the ester monomer thereof can be more efficiently prepared; a supercritical carbon dioxide fluid chromatograph device which takes carbon dioxide at a supercritical state as a chromatographic separation mobile phase, and has constant temperature control, no pulse and very small system dead volume is used for separating compound monomer components. The preparation method and device can be used for high-purity separation preparation of the polyenoic acid and the ester monomer thereof in fish oil, microalgae oil, microorganism oil, plant oil and other bio-oil rough grease. The preparation method and device can be used for guaranteeing high purity of produced products and no solvent residues; and the method is economical, safe and effective.

The invention discloses an emulsion of micron-sized arachidonic acid (ARA)/docosahexenoic acid (DHA) and a preparation method thereof. The emulsion comprises 50g to 150g of ARA and DHA (the ratio of ARA to DHA is 2 to 4), 10g to 100g of oil phase emulsifier, 0.1g to 10g of antioxidant, 5g to 40g of aqueous phase emulsifier, 100g to 300g of thickening and stabilizing agent and 10g to 100g of dispersant; water is added until the solution is 1000g. The emulsion of the invention is O/W type and mainly characterized in that the emulsifiers and the thickening and stabilizing agent are emulsified with the ARA/DHA and water according to certain proportions so as to obtain the emulsion with stable status and emulsified particle diameter less than 1 micron. The invention aims at providing a prescription of an ARA/DHA emulsion which is reasonable in nutrition-allocated proportion and capable of dispersing in cold water, provided with good stability and is stable against light, heat and oxygen and can be conveniently used in beverage and other relevant industries.

The invention discloses a beauty treatment food for women, which is characterized by comprising the following components in parts by weight: 1-3 parts of collagen polypeptide powder, 5-9 parts of vitamin E, 1-3 parts of casein phosphopeptide, 3-5 parts of dry sea cucumber powder, 0.01-0.06 part of antler, 6-8 parts of pawpaw, 8-10 parts of jelly fungi, 3-8 parts of honey, 1-2 parts of ammonium carbonate, 9-13 parts of Jerusalem artichoke powder, 1-2 parts of nard, 2-3 parts of licorice, 1-3 parts of eicosapentaenoic acid, 6-8 parts of walnut powder, 5-8 parts of American ginseng, 50-85 parts of pawpaw powder, 3-9 parts of polyvinylpyrrolidone, 1-2 parts of EDTA-calcium sodium, 3-6 parts of citric acid, 2-6 parts of adipic acid, 3-9 parts of potassium citrate, 1-3 parts of microcrystalline cellulose, 1-2 parts of potassium carbonate, 14-20 parts of edible starch, 1-3 parts of vitamin A and 1-3 parts of honey. By combining the sea cucumber and collagen polypeptide powder and compounding multiple fruits and vegetables, the food has the advantages of high utilization ratio, high absorption speed, obvious effects of crease resistance and beauty treatment, and favorable mouthfeel, is like a jelly paste, is insoluble under heating, and is convenient to eat.

The invention relates to application of arachidonic acid as a xanthine oxidase inhibitor and in the preparation of medicines for treating hyperuricemia or gout. Xanthine oxidase is a key enzyme for the generation and the development of the hyperuricemia or the gout, most substrates of the xanthine oxidase are cyclic small molecules, and the arachidonic acid is long chain polyunsaturated fatty acid; a three dimensional structure of the xanthine oxidase is downloaded from a protein data bank (PDB) of a website; a three dimensional structure of the arachidonic acid is downloaded from a pubchem; molecular docking between the arachidonic acid and the xanthine oxidase is performed by iGEMDOCK software and docking energy is computed; and in-vitro enzyme activity tests prove that the arachidonic acid has an inhibition effect on the xanthine oxidase. By the application, another important physiological function of the arachidonic acid is discovered, and a wider way is provided for screening the xanthine oxidase inhibitor from a natural product to treat the hyperuricemia or the gout simultaneously.

The invention discloses infant nutrition rice flour containing a cymbopogon citrates aqueous extract. The nutrition rice flour comprises the following components in parts by weight: 80-90 parts of long-shaped rice, 10-15 parts of millet, 10-15 parts of whole milk powder, 3-4 parts of whey protein, 2-3 parts of fructo-oligose, 3-4 parts of isomaltooligosaccharide, 0.1-0.3 part of cymbopogon citrates aqueous extract, 8-10 parts of prunus humilis bunge, 4-5 parts of spinach root, 6-8 parts of kiwi fruit, 0.02-0.03 part of docosahexenoic acid, 0.0001-0.0005 part of taurine, 0.0005-0.0006 part of vitamin A, 0.000007-0.000008 part of vitamin D, 0.0005-0.0006 part of vitamin B12, 0.002-0.003 part of nicotinic acid and 0.4-0.6 part of calcium lactate. The rice flour disclosed by the invention is overall in nutrition, good in dissolving quality, smooth in mouthfeel, fragrant, and high in calcium content, can play roles of enhancing the immunity and reducing diseases if the infants frequently eat the rice flour; meanwhile, calcium is also supplied.

A method of making siloxane-based polyamides which includes at least one repeating unit represented by the formulawherein X is a linear or branched C1-C30 alkylene chain; Y is a linear or branched C1-C20 alkylene chain; DP is an integer having a value of 10-500; n is an integer having a value 1-500. The method involves heating an intimate reaction mixture containing an olefinic acid and an organic diamine at a temperature greater than 100° C. and forming an organic diamide; and thereafter reacting the organic diamide with a hydride-terminated polydimethylsiloxane in the presence of a hydrosilylation catalyst to form the siloxane-based polyamide.

The invention relates to organic electroluminescence or charge transport material with side group of unsaturated ester. The general formula is (I), A is electroluminescence or charge transport material, organic semi- conductor main structure, such as piper, or m- TDATA, or poly fluorene benzene; R is alkyl. The synthesis method comprises following steps: introducing hydroxyl group for main structure A of organic semi- conductor, the ester reacting with hydroxyl to produce side group unsaturated ester, rotary coating and filming, crosslinking and curing with ultra- violet. The invention is characterized by low raw material cost, simple reaction, suitability for large- scale production, more stable chemical property and better solubility of product, good liquid processing property, insoluble of crosslinked molecule in organic solution and free from influence from rotary coating of solution on upper layer.

A preparation method of arachidonic acid relates to the arachidonic acid. The method is as follows: optimizing culturing conditions of mortierella alpina arachidonic (ARA), fermenting in batches on basal media, then fermenting in batches on the optimized media by means of using yeast powder and corn steep liquor as nitrogen source, performing a fermenter enlarging experiment by using the yeast powder as the nitrogen source, culturing the mortierella alpina on the optimized media by using the corn steep liquor and the yeast powder as the mixed nitrogen source, and obtaining the mixed nitrogen source optimized media by replacing the nitrogen source on the optimized media into the corn steep liquor and the yeast powder; fermenting the mortierella alpina in batches on the mixed nitrogen source optimized media; performing high-glucose acclimatization to the mortierella alpina and fermenting the acclimated strains in batches on the mixed nitrogen source media; when the concentration of the glucose is reduced to 10g/L, performing fed-batch operation by 600 g/L of glucose so as to control the residual glucose within about 10 g/L, and starting to harvest dry strains, grease and the ARA after culturing for 168 h.

The invention discloses amygdalus pedunculata pall oil as well as an extracting preparation method thereof and application as edible oil. The amygdalus pedunculata pall oil comprises the following components according by weight percent: 1.9% of palmitic acid, 0.4% of palmitoleic acid, 66.5% of oleic acid, 29.2% of linoleic acid, 0.8% of linolenic acid, 0.4% of peanut olefine acid and 0.8% of erucic acid. The extracting method of the amygdalus pedunculata pall oil comprises the following steps of: (1) drying amygdalus pedunculata pall seeds to remove seed coats at 40-100 DEG C; (2) adding bran accounting for 1-3% of the mass of seeds after removing the seed coats, squeezing for several times (twice to four times) by a hydraulic oil mill at low temperature, combining and then filtering the oil squeezed for several times to obtain the amygdalus pedunculata pall oil. In the invention, the amygdalus pedunculata pall oil has excellent tupical properties and abundant nutrient elements and can be developed to be high-quality edible oil.

A nerve-regenerating agent comprising, as an active ingredient, arachidonic acid and/or a compound containing arachidonic acid as a constituent fatty acid.

According to a technical scheme on the first aspect, the invention provides a drug for treatment of polycystic ovary syndrome (PCOS) and abnormal glucose metabolism coexisting diseases. The drug is characterized by including the following four fatty acid components by mass: 17-22% of palmitic acid, 11-23% of hexadecenoic acid, 22-28% of 9-octadecenoic acid, 13-35% of 9, 12, 15-octatecatrienoic acid, and the balance pharmaceutically acceptable additives or excipients. The components are mixed according to compatibility to be prepared into soft capsules and other oral preparations, so that the insulin receptor substrate (IRS) protein level can be effectively reduced so as to inhibit the glucose way, the insulin receptor active time can be increased and the insulin level can be enhanced, and the insulin sensitivity is increased so as to facilitate the reduction of insulin resistance degree. Thus, the drug can have the functions of improving and recuperating ovary ovulatory dysfunction, i.e. PCOS and abnormal glucose metabolism diseases. Compared with other drugs, the drug has simple components, and belongs to highly effective, safety, and simplified drugs.

The invention discloses a method for preparing 11-bromo-undecanoic acid by direct freezing crystallization and a device for preparing 11-bromo-undecanoic acid, and relates to a method for preparing the 11-bromo-undecanoic acid. The preparation device comprises a burdening kettle, an addition tower, a crystallization kettle and a filter press, wherein the burdening kettle is connected with the addition tower; the addition tower is connected with the crystallization kettle; the crystallization kettle is connected with the filter press; and the filter press is connected with the top part of the burdening kettle. During work, the preparation method comprises the steps of: mixing undecylenic acid and toluene in a mass ratio of 1:(3-4) at a temperature of -5-0 DEG C in the burdening kettle; allowing the mixed liquid with hydrogen bromide in a mole ratio of 1:1.05 at a temperature of 0-30 DEGC in the addition tower to react so as to generate an addition liquid; putting the addition liquid in the crystallization kettle, carrying out freezing crystallization at a temperature of -4 DEG C to -16 DEG C, a revolving speed of 8 round/min and a vacuum degree of -0.02MPa to -0.03MPa; and filtering crystal in the filter press. The device disclosed by the invention has the advantages of a simple structure, strong continuity and operability and is suitable for industrial production. The preparation method has the advantages of a short process flow, constant reaction, high product purity and good economic benefits.

The present invention relates to a nutrient powder. Its composition contains fresh milk (dried weight) 15.3694-21.7307%, soy-bean 17.8396-24.2918%, white granulated sugar 33.6713-45.4389%, malt syrup(dried weight) 10.0405-13.6085%, vegetable oil 3.0121-4.9485%, maltodextrine (dred weight) 4.0162-6.1857%, arachidonic acid 0.0398-0.1127%, decosahexenoic acid 0.0199-0.0501%, nutrient complex 0.0219-0.0826%, microcapsule untioxidant 0.0001-0.0008% and microcapsules carrier 0.2501-1.1183%.

A composition that has an activity of ameliorating reduced higher brain functions resulting from organic brain lesions, said composition comprising arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid as well as docosahexaenoic acid and/or a compound having docosahexaenoic acid as a constituent fatty acid.